Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma

被引：2
|
作者：
Diab, A. [1 ]
Abdel-Wahab, N. [2 ,3 ]
Bentebibel, S. E. [1 ]
Montazari, E. J. [1 ]
Spillson, C. A. [1 ]
Ekmekcioglu, S. [1 ]
Gao, J. [4 ]
Altan, M. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Gen Internal Med Melanoma Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169TiP
引用
收藏
页码：S1456 / S1456
页数：1
相关论文
共 50 条
  • [21] The Efficacy and Safety of Nivolumab, Pembrolizumab, and Atezolizumab in Treatment of Advanced Non-small Cell Lung Cancer
    Chen, Rui
    Tao, Yuquan
    Xu, Xin
    Shan, Liang
    Jiang, Hongyuan
    Yin, Qilei
    Pei, Lingyan
    Cai, Feng
    Ma, Lifang
    Yu, Yongchun
    DISCOVERY MEDICINE, 2018, 26 (143) : 155 - 166
  • [22] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [24] Treatment of advanced non-small cell lung cancer
    De Petris, L
    Crinò, L
    Scagliotti, GV
    Gridelli, C
    Galetta, D
    Metro, G
    Novello, S
    Maione, P
    Colucci, G
    de Marinis, F
    ANNALS OF ONCOLOGY, 2006, 17 : 36 - 41
  • [25] Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease
    Satoh, Hiroaki
    Hattori, Sou
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (02): : 155 - 156
  • [26] Prospective Evaluation of Ipilimumab and Nivolumab in Patients with Non-Small Cell Lung Cancer Brain Metastasis
    Juloori, A.
    Bestvina, C.
    Pitroda, S.
    Pointer, K.
    Jelinek, M.
    Hoffman, P.
    Vokes, E.
    Patel, J.
    Chmura, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S45 - S45
  • [27] The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
    Tanvetyanon, Tawee
    Creelan, Benjamin C.
    Antonia, Scott J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 903 - 910
  • [28] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [29] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [30] Efficacy and safety of first-line ipilimumab and nivolumab treatment in elderly patients with non-small cell lung cancer
    Imai, H.
    Mouri, A.
    Endo, S.
    Tsukamoto, K.
    Masaki, K.
    Hashimoto, K.
    Miura, Y.
    Shiono, A.
    Yamaguchi, O.
    Nakagawa, J.
    Kaira, K.
    Kobayashi, K.
    Kagamu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1649 - S1649
12345